Quality of Life of Patients with Type I Diabetes Mellitus

Overview

Journal Qual Life Res

Specialties Pharmacology
Rehabilitation Medicine

Date 2003 Dec 4

PMID 14651426

Citations 28

Authors

H E Hart

H J G Bilo

W K Redekop

R P Stolk

J H Assink

B Meyboom-de Jong

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to assess health related quality of life (QOL) in patients with type I diabetes mellitus (DMT1) and to compare their QOL with the QOL of persons of comparable age in the general population. Furthermore we wanted to investigate which factors mostly influence QOL. In a Dutch cohort of 281 patients with DMT1 QOL was assessed using two generic instruments: the EuroQol and the RAND-36. We performed regression analyses to investigate relationships between several demographic (e.g. sex, age, marital status) and diabetes-specific variables (e.g. HbA1c, frequency of insulin injection, presence of acute and chronic complications) and QOL. The Spearman rank correlations between RAND-36 domains and EuroQol were analysed. RAND-36 results showed, for almost all domains, a QOL comparable with persons of comparable age in the general population. In contrast the QOL measured with the EuroQol was lower for subjects with DMT1. Hyperglycaemic complaints and macrovascular complications had a profound negative influence on QOL. Most correlations between the RAND-36 results and the EuroQol results corresponded with our expectations. Longitudinal data and comparison with results of several diabetes-specific questionnaires should help to establish which instrument might be most appropriate to measure QOL in patients with DMT1.

Citing Articles

Comparing quality of life in traditional face-to-face visits with a hybrid approach of telemedicine with in-person follow-ups in recent users of advanced closed-loop systems: a randomized controlled clinical trial in patients with type 1 diabetes.

Nattero-Chavez L, de La Calle E, Lecumberri-Pascual E, Bayona Cebada A, Ruiz Gracia T, Quintero Tobar A Ther Adv Endocrinol Metab. 2024; 15:20420188241288789.

PMID: 39493410 PMC: 11528595. DOI: 10.1177/20420188241288789.

Volcansek S, Lunder M, Janez A Healthcare (Basel). 2023; 11(15).

PMID: 37570394 PMC: 10418676. DOI: 10.3390/healthcare11152154.

Controlling glycemic variability in people living with type 1 diabetes receiving insulin glargine 300 U/mL (Gla-300).

Mader J, Golz S, Bilz S, Bramlage P, Danne T BMJ Open Diabetes Res Care. 2022; 10(4).

PMID: 36007982 PMC: 9422797. DOI: 10.1136/bmjdrc-2022-002898.

Hypomagnesemia in persons with type 1 diabetes: associations with clinical parameters and oxidative stress.

van Dijk P, Waanders F, Qiu J, de Boer H, van Goor H, Bilo H Ther Adv Endocrinol Metab. 2021; 11:2042018820980240.

PMID: 33447354 PMC: 7780304. DOI: 10.1177/2042018820980240.

Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes.

Markmann J, Rickels M, Eggerman T, Bridges N, Lafontant D, Qidwai J Am J Transplant. 2020; 21(4):1477-1492.

PMID: 32627352 PMC: 9074710. DOI: 10.1111/ajt.16174.

References

Guyatt G, Feeny D, Patrick D . Measuring health-related quality of life. Ann Intern Med. 1993; 118(8):622-9. DOI: 10.7326/0003-4819-118-8-199304150-00009. View

Luscombe F . Health-related quality of life measurement in type 2 diabetes. Value Health. 2006; 3 Suppl 1:15-28. DOI: 10.1046/j.1524-4733.2000.36032.x. View

Hanestad B . Self-reported quality of life and the effect of different clinical and demographic characteristics in people with type 1 diabetes. Diabetes Res Clin Pract. 1993; 19(2):139-49. DOI: 10.1016/0168-8227(93)90107-g. View

Ware J, Kosinski M . Interpreting SF-36 summary health measures: a response. Qual Life Res. 2002; 10(5):405-13; discussion 415-20. DOI: 10.1023/a:1012588218728. View

Garratt A, Schmidt L, Fitzpatrick R . Patient-assessed health outcome measures for diabetes: a structured review. Diabet Med. 2002; 19(1):1-11. DOI: 10.1046/j.1464-5491.2002.00650.x. View

REICHARD P, Nilsson B, Rosenqvist U . The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993; 329(5):304-9. DOI: 10.1056/NEJM199307293290502. View

Aaronson N, Muller M, Cohen P, Essink-Bot M, Fekkes M, Sanderman R . Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998; 51(11):1055-68. DOI: 10.1016/s0895-4356(98)00097-3. View

. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group. Diabetes Care. 1999; 22(7):1125-36. DOI: 10.2337/diacare.22.7.1125. View

. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994; 37(3):278-85. DOI: 10.1007/BF00398055. View

10.

Wandell P, Brorsson B, Aberg H . Quality of life among diabetic patients in Swedish primary health care and in the general population: comparison between 1992 and 1995. Qual Life Res. 1999; 7(8):751-60. DOI: 10.1023/a:1008893121086. View

11.

Bott U, Muhlhauser I, Overmann H, Berger M . Validation of a diabetes-specific quality-of-life scale for patients with type 1 diabetes. Diabetes Care. 1998; 21(5):757-69. DOI: 10.2337/diacare.21.5.757. View

12.

Hahl J, Hamalainen H, Sintonen H, Simell T, Arinen S, Simell O . Health-related quality of life in type 1 diabetes without or with symptoms of long-term complications. Qual Life Res. 2002; 11(5):427-36. DOI: 10.1023/a:1015684100227. View

13.

Patrick D, Deyo R . Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989; 27(3 Suppl):S217-32. DOI: 10.1097/00005650-198903001-00018. View

14.

Reviriego J, Millan M, Millan M . Evaluation of the diabetes quality-of-life questionnaire in a Spanish population. An experience of translation and reliability. Pharmacoeconomics. 1996; 10(6):614-22. DOI: 10.2165/00019053-199610060-00007. View

15.

Rubin R, Peyrot M . Quality of life and diabetes. Diabetes Metab Res Rev. 1999; 15(3):205-18. DOI: 10.1002/(sici)1520-7560(199905/06)15:3<205::aid-dmrr29>3.0.co;2-o. View

16.

Redekop W, Koopmanschap M, Stolk R, Rutten G, Wolffenbuttel B, Niessen L . Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care. 2002; 25(3):458-63. DOI: 10.2337/diacare.25.3.458. View

17.

Wu S, Sainfort F, Tomar R, Tollios J, Fryback D, Klein R . Development and application of a model to estimate the impact of type 1 diabetes on health-related quality of life. Diabetes Care. 1998; 21(5):725-31. DOI: 10.2337/diacare.21.5.725. View

18.

Hays R, Sherbourne C, Mazel R . The RAND 36-Item Health Survey 1.0. Health Econ. 1993; 2(3):217-27. DOI: 10.1002/hec.4730020305. View

19.

Eiser C, Tooke J . Quality-of-life evaluation in diabetes. Pharmacoeconomics. 1993; 4(2):85-91. DOI: 10.2165/00019053-199304020-00003. View

20.

Coons S, Rao S, Keininger D, Hays R . A comparative review of generic quality-of-life instruments. Pharmacoeconomics. 2000; 17(1):13-35. DOI: 10.2165/00019053-200017010-00002. View